Gennev recently commissioned Milliman to conduct an analysis to quantify the medical and pharmacy costs and utilization of U.S. women aged 45 to 54 who have employer-sponsored health insurance and have been diagnosed with or are being treated for menopause or perimenopause. The report is intended to identify the healthcare economic profiles of women in menopause who have used specific types of therapy, including hormone-replacement therapy, nonhormonal therapy, or no therapy at all for their menopause symptoms. Administrative healthcare claims data was summarized from Milliman’s nationwide commercial data set for calendar year 2021 across seven populations.

This report was commissioned by Gennev.